BrainStorm Cell Therapeutics Inc. Appoints Hartoun Hartounian Ph.D. as EVP and COO
PUBLIC · BCLIJun 20, 2024
Company
Brainstorm Cell Therapeutics
New YorkBiotechnologyHealth CareTherapeuticsresearch
Description
BrainStorm Cell Therapeutics Inc. announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024
Company Information
Company
Brainstorm Cell Therapeutics
Location
1325 Avenue of Americas, 28th Floor
New York, New York, United States
About
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
Fundz sees it the moment Brainstorm Cell Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.